. 2020 Jan 28;11(2):172–178. doi: 10.1021/acsmedchemlett.9b00552

Table 2. Detailed Profile of Compound 10^a.

Assay	Result
Hu T-cell pSMAD3 IC₅₀ (μM)	0.15
NIH3T3 pSMAD3 IC₅₀ (μM)	0.05
Hu Treg FoxP3⁺ IC₅₀ (μM)	0.23
AMES result	Negative
LM T_1/2 (NADPH, min) mouse, rat, dog, human	28, 50, 37, 23
LM T_1/2 (UGT/UDPGA, min) mouse, rat, dog, human	>120, >120, 92, >120
Hepatocyte T_1/2 (min) mouse, rat, dog, human	76, 320, 62, 54
Protein binding (% free fraction): mouse, rat, dog, human	12, 10, 13, 10
rCYP 450 inhibition IC₅₀ (μM) 1A2, 2C8, 2C9, 2C19, 2D6, 3A4	>20, >20, >20, >20, >20, >20, >20
hERG EP IC₅₀ (μM)	>10
PXR (EC₅₀, μM & Y_max)	>24/44
aq. solubility at pH 6.5 (μg/mL)	47
In vitro safety panel (IC₅₀)	>25 μM except PDE4 (11 μM) out of 46 tested

The TGFβR1, TGFβR2, MINK SMAD, and NHLF SMAD IC₅₀s for compound 10 are reported on the last line of Table 1.

Table 2. Detailed Profile of Compound 10a.